Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis*. 2000;30(4):633–638.

Licht DJ, Shera DM, Clancy RR, et al. Brain maturation is delayed in infants with complex congenital heart defects. *J Thorac Cardiovasc Surg*. 2009;137(3):529–536.

Longmuir PE, Brothers JA, de Ferranti SD, et al. Promotion of physical activity for children and adults with congenital heart disease: a scientific statement from the American Heart Association. *Circulation*. 2013;127(21):2147–2159.

Majnemer A, Limperopoulos C. Developmental progress of children with congenital heart defects requiring open heart surgery. *Semin Pediatr Neurol*. 1999;6(1):12–19.

Margossian R. Contemporary management of pediatric heart failure. *Expert Rev Cardiovasc Ther*. 2008;6(2):187–197.

Marijon E, Mirabel M, Celermajer DS, et al. Rheumatic heart disease. *Lancet*. 2012;379(9819):953–964.

Maron BJ. Hypertrophic cardiomyopathy. Allen HD, Driscoll DJ, Shaddy RE, et al. *Moss and Adams' heart disease in infants, children, and adolescents*. ed 6. Lippincott Williams & Wilkins: Philadelphia; 2001.

Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens, and outcomes. *Expert Rev Anti Infect Ther*. 2012;10(6):701–706.

McCrindle BW, Kwiterovich PO, McBride PE, et al. Guidelines for lipid screening in children and adolescents: bringing evidence to the debate. *Pediatrics*. 2012;130(2):353–356.

McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. *Circulation*. 2007;115(14):1948–1967.

Mickley KL, Burkhart PV, Sigler AN. Promoting normal development and self-efficacy in the school-age children managing chronic conditions. *Nursing Clin North Am*. 2013;48(2):319–328.

Nakase JY. Update on emerging infections from the Centers